Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)

Elena Dozio; Valentina Corradi; Marta Proglio; Elena Vianello; Lorenzo Menicanti; Roberta Rigolini; Carlotta Caprara; Massimo de Cal; Massimiliano M. Corsi Romanelli; Claudio Ronco

doi:10.1016/j.diabres.2018.03.017

Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)

Elena Dozio, Valentina Corradi, Marta Proglio, Elena Vianello, Lorenzo Menicanti, Roberta Rigolini, Carlotta Caprara, Massimo de Cal, Massimiliano M. Corsi Romanelli, Claudio Ronco

IRCCS Policlinico San Donato

Research output: Contribution to journal › Review article

Abstract

In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis.

Original language	English
Pages (from-to)	9-17
Number of pages	9
Journal	Diabetes Research and Clinical Practice
Volume	140
DOIs	https://doi.org/10.1016/j.diabres.2018.03.017
Publication status	Published - Jun 1 2018

Keywords

Cardiovascular risk
Diabetes
Dialysis
Glycated albumin
Glycation
Hemodialysis
Mortality
Peritoneal dialysis

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1016/j.diabres.2018.03.017

Fingerprint Dive into the research topics of 'Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)'. Together they form a unique fingerprint.

Cite this

Dozio, E., Corradi, V., Proglio, M., Vianello, E., Menicanti, L., Rigolini, R., Caprara, C., de Cal, M., Corsi Romanelli, M. M., & Ronco, C. (2018). Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D). Diabetes Research and Clinical Practice, 140, 9-17. https://doi.org/10.1016/j.diabres.2018.03.017

Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D). / Dozio, Elena; Corradi, Valentina; Proglio, Marta; Vianello, Elena; Menicanti, Lorenzo; Rigolini, Roberta; Caprara, Carlotta; de Cal, Massimo; Corsi Romanelli, Massimiliano M.; Ronco, Claudio.

In: Diabetes Research and Clinical Practice, Vol. 140, 01.06.2018, p. 9-17.

Research output: Contribution to journal › Review article

Dozio, E, Corradi, V, Proglio, M, Vianello, E, Menicanti, L, Rigolini, R, Caprara, C, de Cal, M, Corsi Romanelli, MM & Ronco, C 2018, 'Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)', Diabetes Research and Clinical Practice, vol. 140, pp. 9-17. https://doi.org/10.1016/j.diabres.2018.03.017

Dozio, Elena ; Corradi, Valentina ; Proglio, Marta ; Vianello, Elena ; Menicanti, Lorenzo ; Rigolini, Roberta ; Caprara, Carlotta ; de Cal, Massimo ; Corsi Romanelli, Massimiliano M. ; Ronco, Claudio. / Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D). In: Diabetes Research and Clinical Practice. 2018 ; Vol. 140. pp. 9-17.

@article{ab7a1363ae0747e280aa33608be4f38c,

title = "Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)",

abstract = "In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis.",

keywords = "Cardiovascular risk, Diabetes, Dialysis, Glycated albumin, Glycation, Hemodialysis, Mortality, Peritoneal dialysis",

author = "Elena Dozio and Valentina Corradi and Marta Proglio and Elena Vianello and Lorenzo Menicanti and Roberta Rigolini and Carlotta Caprara and {de Cal}, Massimo and {Corsi Romanelli}, {Massimiliano M.} and Claudio Ronco",

year = "2018",

month = jun,

day = "1",

doi = "10.1016/j.diabres.2018.03.017",

language = "English",

volume = "140",

pages = "9--17",

journal = "Diabetes Research and Clinical Practice",

issn = "0168-8227",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)

AU - Dozio, Elena

AU - Corradi, Valentina

AU - Proglio, Marta

AU - Vianello, Elena

AU - Menicanti, Lorenzo

AU - Rigolini, Roberta

AU - Caprara, Carlotta

AU - de Cal, Massimo

AU - Corsi Romanelli, Massimiliano M.

AU - Ronco, Claudio

PY - 2018/6/1

Y1 - 2018/6/1

N2 - In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis.

AB - In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis.

KW - Cardiovascular risk

KW - Diabetes

KW - Dialysis

KW - Glycated albumin

KW - Glycation

KW - Hemodialysis

KW - Mortality

KW - Peritoneal dialysis

UR - http://www.scopus.com/inward/record.url?scp=85050301841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050301841&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2018.03.017

DO - 10.1016/j.diabres.2018.03.017

M3 - Review article

C2 - 29596954

AN - SCOPUS:85050301841

VL - 140

SP - 9

EP - 17

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

ER -